Real-life management of atopic dermatitis patients with an inadequate response to on-label use of dupilumab

Real-life management of atopic dermatitis patients with an inadequate response to on-label use of dupilumab

In patients with moderate to severe atopic dermatitis (AD) showing an inadequate response to dupilumab 300mg/2weeks, few real-life studies reported the response to alternative regimen maintaining dupilumab.To assess and analyze the response to an increased dose of dupilumab or its combination with c...

Full description

Bibliographic Details
Main Authors: Rémi Strizzolo, MD, Julien Seneschal, MD, PhD, Angèle Soria, MD, PhD, Delphine Staumont-Sallé, MD, PhD, Sébastien Barbarot, MD, PhD, Manuelle Viguier, MD, PhD, Marie Jachiet, MD, Audrey Nosbaum, MD, PhD, Aude Clément, MD, Marie Tauber, MD, PhD, Stéphanie Mallet, MD, Aurélie Du-Thanh, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-07-01
Series:World Allergy Organization Journal
Subjects:
Dermatitis
Atopic
Dupilumab
Cyclosporine
Methotrexate
Itraconazole
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455124000541

Internet

http://www.sciencedirect.com/science/article/pii/S1939455124000541

Similar Items